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Depression of myocardial function during severe sepsis, which currently accounts for
approx. 200,000 deaths/year in the United States (1), is characterized by a decrease in
contractility and a poor response to fluid therapy (2). Since the md-1980s it has been
recognized that the decreased cardiac function, which undoubtedly contributes to the overall
pathophysiology of the septic state, does not arise from factors that are intrinsic to the
myocardium, but instead results from the presence of circulating myocardial depressant
factors (3, 4). Since much of the massive inflammation and multi-organ dysfunction in
sepsis result from the secretion of various cytokines, it was long suspected that these
proteins were also responsible, at least in part, for the observed myocardial dysfunction,
although their identification, and the molecular basis for their effects on myocyte function
were poorly understood.
Pathan and colleagues recently showed that the cytokine IL-6 is a major factor responsible
for modulating myocardial depression in children with meningococcal septicemia (5). In this
issue of Critical Care Medicine, Pathan et al., use an in-vitro cardiac myocyte cell culture
system to investigate the signaling pathways (and potential drug targets) that modulate and/
or are modulated by IL-6 (new article). They report that the stress activated p38 mitogen
activated protein kinase (p38 MAPK) pathway controls IL-6-induced myocardial depression
and that this can be reversed using a specific chemical inhibitor of this kinase (SB203580).
The authors go on to look at gene expression changes in a small cohort of pediatric patients
with meningococcal sepsis and find a number of differences between septic patients and
healthy controls. Amongst the genes that show differential expression are a number of
upstream and downstream regulators of p38 MAPK signaling indicating that this pathway is
deregulated in this cohort of patients. However, the mechanism by which such a large group
of genes involved in p38 MAPK signaling could be deregulated remains to be determined.
In addition to the work of Pathan et al., are a number of observations that link p38 MAPK
and one of it’s downstream kinases, MK2 (MAPKAPK2) to the control of IL-6 biosynthesis
(6). For example, during LPS-induced inflammation p38 MAPK activates MK2, which in
turn controls IL-6 production by stabilizing the IL-6 messenger RNA (7). Therefore the p38
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MAPK/MK2 pathway appears to lie both upstream and downstream of IL-6 in inflammation
and sepsis.
These observations are of obvious clinical relevance since p38 MAPK and its downstream
effectors are under intense scrutiny as viable drug targets for the treatment of a number of
diseases from colitis to cancer (6, 8, 9). The current study further highlights the potential
utility of p38 MAPK inhibitors in the specific management of sepsis-associated cardiac
dysfunction. p38 MAPK, however, activates a variety of downstream effectors that affect a
wide variety of other cellular responses during sepsis in addition to cytokine secretion and
myocardial contractility, including effects on apoptosis and neutrophil function (10, 11). In
this regard, drugs that target the specific components of the p38 MAPK pathway that are
central to its IL-6 effects, such as MK2 or its substrates, may also show promise in the
clinical treatment of sepsis by preventing IL-6 production thus inhibiting myocardial
depression, while having fewer effects on other p38 MAPK-dependent responses. In this
regard emerging new drugs targeting IL-6 itself, such as IL-6 blocking monoclonal
antibodies (12), may also show utility in this setting. Importantly the utility of these drugs
will not be limited to myocardial dysfunction in sepsis since the p38 MAPK/MK2/IL6
pathway appears to be a major determinant of response to chemotherapy in certain cancers
(13, 14). For example, p38 MAPK-dependent IL-6 secretion from thymic endothelial cells
mediates drug resistance and relapse in a mouse model of Burkitt’s lymphoma (15).
Therefore new drugs targeting the p38 MAPK-MK2-IL-6 signaling pathway may have a
broader utility in cancer treatment as well as for the treatment of conditions where chronic
inflammation is a major driving force of the diseased state, such as sepsis. If such drugs
prove useful, it will be yet another example of how agents that were developed to limit the
pathology of inflammation, such as cyclooxygenase inhibitors, can have a double life in
clinical oncology. That indeed would be quite a lot of heart to salvage.
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